GlassScriptPhysician profile
Brooke Barker Long
NPI 1558089813
$6,464.68
in general payments reported to CMS, 2019-2025
33 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $100 · 2023: $1,864 · 2024: $2,292 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,364.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $911.93 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $833.43 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $551.11 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $539.26 | 2023-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $348.13 | 2023-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $342.56 | 2023-2025 | Rystiggo, Briviact |
| Tg Therapeutics, INC. | $324.99 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $269.20 | 2023-2025 | Nuplazid |
| Lilly USA, LLC | $210.52 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Otsuka America Pharmaceutical, INC. | $195.30 | 2023-2025 | Rexulti |
| Pfizer INC. | $193.15 | 2023-2025 | |
| Argenx US, INC. | $184.78 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Catalyst Pharmaceuticals, INC. | $166.68 | 2023-2025 | Fycompa |
| Eisai INC. | $157.98 | 2022-2025 | |
| Genentech USA, INC. | $145.64 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Evrysdi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $139.29 | 2025 | Ultomiris |
| Impel Pharmaceuticals INC. | $128.29 | 2023 | Trudhesa |
| Lundbeck LLC | $111.33 | 2023-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $90.28 | 2023-2025 | Valtoco |
| Stryker Corporation | $73.35 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amneal Pharmaceuticals LLC | $66.28 | 2023-2025 | Crexont, Lyvispah |
| Amgen INC. | $62.10 | 2024-2025 | Uplizna |
| Emd Serono, INC. | $61.32 | 2023-2025 | Mavenclad |
| Biogen, INC. | $52.16 | 2025 | Vumerity, Tysabri |
| Csl Behring | $51.08 | 2024 | Hizentra |
| Livanova USA, INC. | $41.95 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Hospital Products INC. | $36.10 | 2024 | Acthar |
| Medtronic, INC. | $34.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.20 | 2022 | |
| Genzyme Corporation | $29.22 | 2023 | |
| Sk Life Science, INC. | $28.48 | 2024 | |
| Vanda Pharmaceuticals INC. | $26.35 | 2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $25.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.